Defining outcomes for beta cell replacement therapy: a work in progress.
Piemonti LDiabetes Research Institute, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy. piemonti.lorenzo@hsr.it.
de Koning EJPDepartment of Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Berney TDivision of Transplantation and Visceral Surgery, Department of Surgery, Geneva University Hospital, Geneva, Switzerland.
Odorico JSDivision of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Markmann JFDivision of Transplantation, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Stock PGDivision of Transplantation, Department of Surgery, University of California at San Francisco, San Francisco, CA, USA.
Rickels MRDivision of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
English
Defined outcomes for beta cell replacement therapy in the treatment of diabetes are critically needed. Progress towards the clinical acceptance of pancreas and islet transplantation has been hampered by the lack of clear definitions of functional and efficacy outcomes, as well as a lack of consistently applied glycaemic control metrics, together with poor alignment with the field of artificial insulin delivery/artificial pancreas development. To address this problem, the International Pancreas & Islet Transplant Association (IPITA) collaborated with the European Pancreas and Islet Transplant Association (EPITA) to develop a consensus for a joint statement on the definition of function and failure of beta cell replacement therapies, which is summarised in this commentary.